nPhase launched an AI platform aimed at accelerating regulatory submissions for clinical trials by converting raw study data into submission-ready information. The company claims the workflow can speed processes by 75% to 80% versus traditional methods. For biopharma teams preparing IND and NDA packages, the central question will be how quickly AI outputs can be validated, audited, and mapped to regulatory formatting requirements without undermining data integrity. nPhase’s positioning centers on reducing operational bottlenecks in late-stage documentation cycles.